Dr. Gregory Kirk, Consortium Principal Investigator, is a Professor of Epidemiology, Medicine and Oncology at Johns Hopkins University. Dr. Kirk’s research focuses on understanding and preventing the long-term consequences of chronic HIV infection, particularly the malignant complications of HIV and viral hepatitis. He has extensive research and clinical experience in Africa, leading the Gambia Liver Cancer Study, one of the largest studies of HCC performed in the continent, in addition to years of collaborative research in Uganda. He pioneered the use of elastography and application of novel aflatoxin-associated biomarkers of HCC risk to be applied in Consortium projects. He has strong, multidisciplinary team leadership skills as PI of the ALIVE cohort and several other collaborative studies in Baltimore.
Dr. David Thomas, Co-Principal Investigator, Project 2, is the Chief of the Division of Infectious Diseases at Hopkins and an internationally-recognized expert in HIV and hepatitis co-infection. In 2005-06, he spent a year in Kampala as the Director of Research for the Infectious Diseases Institute where he worked closely with Drs. Ocama, Seremba and Opio. As Co-PI for Project 2, he will provide overall senior expertise and technical support for the fibrosis and HCC screening studies and supervise the HCV viral load testing.
Dr. John Groopman, Principal Investigator, Biomarker / Analytical Core, is the Associate Director of Cancer Prevention and Control for the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, former Chair of the Department of Environmental Health, and an international expert in the molecular pathogenesis and biomarkers of aflatoxin exposure. In addition to contributing to the Developmental Core, he will serve as Hopkins PI for the Biomarker/Analytical Core.
Dr. Tom Quinn, Principal Investigator, Developmental Core, Director of the Johns Hopkins Center for Global Health and the NIAID Uganda ICER, is a world-renowned leader in the study of HIV. His involvement solidifies the close interaction between the proposed studies and the on-going NIAID Bench-to-Bedside projects. In addition to providing senior guidance, he will be the Hopkins PI for the Developmental Core.
Dr. Yuka Manabe, Co-Investigator, is an infectious diseases physician at Hopkins with clinical and translational research expertise, and spent 4 years in Uganda as Head of Research for IDI. She will provide invaluable support for navigating, administering, and providing oversight to conduct of clinical and laboratory-based research at IDI as part of Project 2.
Dr. Chloe Thio, Co-Investigator, is an infectious disease physician at Johns Hopkins, is an international leader in HBV virology and in the clinical management of HIV/HBV co-infection. She leads multiple NIH grants focused on pathogenesis and management of HIV/HBV coinfection in the US and in international sites. As part of the Biomarker/Analytical Core, Dr. Thio will be provide guidance on transferring the technical capacity for the molecular virology biomarkers, particularly for the HBV viral load, genotyping and mutation assays.
Dr. Jim Aizire, Co-Investigator (H2U projects 1 and 2), holds a medical degree from Makerere University and a Master’s of Health Science in Epidemiology from Johns Hopkins University. He is currently a doctoral candidate in the department of Epidemiology at Hopkins. He has more than 10 years of leading HIV research through the MUJHU (Makerere University-Johns Hopkins University) partnership. Dr. Aizire’s responsibilities include facilitation and support of Dr. Kirk’s activities as co-Leader. As a member of the Management Team, Dr. Aizire also assists in monitoring study progress, regulatory compliance and progress reporting, data management and analysis, enhance site communications, and performs other study related activities as necessary.